Dr. Tempero on New Therapies for Pancreatic Cancer

Margaret A. Tempero, MD
Published Online: Monday, January 13, 2014
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer.

Tempero says that stromal depleting agents are also in development. There is also an interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment.

Online CME Activities
Free CME from PER
Angiogenesis Inhibitors for Gastrointestinal Cancers: Update From the 2015 Gastrointestinal Cancers Symposium
Cancer Summaries and Commentaries™: Updates from San Francisco in Acute Myeloid Leukemia
Community Practice Connections: 9th Annual New York Lung Cancer Symposium®
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
More Reading
$auto_registration$